Olympus Stock Earnings Reports

Q1 FY2026 was a weak start: consolidated revenue fell 12% YoY to JPY206.5B and adjusted operating profit declined 65% YoY to JPY13.2B (adjusted margin 6.4%). Major drivers were tough comparables in North America (prior-year EVIS X1 launch and backlog clean-up), purchaser delays ahead of anticipated new product launches (notably the EDOF scope), softness in Japan and China (Buy China policy and intensified competition), and cost headwinds from newly announced US tariffs and FDA import alerts. Management expects product-driven recovery in H2—new launches (EDOF scopes, EU‑ME3, Slim EBUS, VISERA ELITE III, THUNDERBEAT2) and an improving pipeline in the US—but has revised FY2026 guidance to reflect tariff and import-alert impacts. CFO estimates the gross impact of US tariffs at ~JPY26B on cost of sales (net ~JPY16B after mitigation) and forecasts adjusted operating profit of JPY157B for FY2026 with full‑year revenue ~JPY998B (roughly flat YoY, ~+3% after FX). Cash flow was weak in Q1 (operating cash flow -JPY15.2B; free cash flow -JPY32.7B; adjusted free cash flow -JPY70.5B excluding extraordinary items) but management expects recovery from Q2 with tighter SG&A discipline (commitment that SG&A growth will not exceed revenue growth), structural cost reforms, and continued innovation investment. Quality/regulatory program PJ Elevate is reported ~96% complete against FDA commitments; management expects completion within FY2026 and is preparing for FDA re‑inspection. Strategic move: formation of Swan EndoSurgical (45% stake) with Revival Healthcare Capital to accelerate endoluminal robotics (GI focus), treated as equity‑method investment. Shareholder returns unchanged: year‑end dividend JPY30 (+JPY10) and JPY50B buyback planned. Management priorities: complete PJ Elevate and FDA re‑inspection, protect the bottom line via cost measures, and continue investing in innovation.